Wu Xiaolan, Liu Qizhi, Jiang Zhili, Wang Guiyun, Liao Lingyu, Ye Xiaojuan, Xing Min, Sun Han, Liu Qiying, Liu Huiping
School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Hunan Provincial Key Laboratory of Traditional Chinese Medicine Prescription and Syndrome Differentiation Translational Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Front Immunol. 2025 Jun 5;16:1578723. doi: 10.3389/fimmu.2025.1578723. eCollection 2025.
Ovarian cancer(OC) is the second most common gynecological malignancy worldwide. While traditional treatments such as cytoreductive surgery, chemotherapy, and targeted drugs have made progress, patients with advanced disease still face high recurrence rates and resistance to treatment. As a result, there is an urgent need to develop new therapeutic strategies. Ferroptosis, a novel form of programmed cell death characterized by iron-dependent lipid peroxidation, has recently gained attention for its potential in cancer therapy. Studies indicate that OC cells are highly sensitive to ferroptosis, and targeting this pathway can effectively overcome chemotherapy resistance and improve treatment outcomes. This review systematically examines the molecular mechanisms of ferroptosis and its role in OC, with a focus on its involvement in tumor initiation, progression, TME and resistance. Furthermore, we highlight the research advancements on various ferroptosis inducers, including natural products, small molecule compounds, and nanotechnology, and explore their potential in overcoming resistance and enhancing patient prognosis. We also discuss the challenges facing ferroptosis-based treatments for OC, such as species differences, drug resistance, personalized treatment needs, and clinical translation issues. Ultimately, targeted modulation of ferroptosis offers new hope for OC therapy. Future research should focus on further elucidating its molecular mechanisms and exploring effective inducers and combination therapies to enhance its clinical applicability in precision and personalized medicine.
卵巢癌(OC)是全球第二常见的妇科恶性肿瘤。尽管细胞减灭术、化疗和靶向药物等传统治疗方法取得了进展,但晚期患者仍面临高复发率和治疗耐药性。因此,迫切需要开发新的治疗策略。铁死亡是一种以铁依赖性脂质过氧化为特征的新型程序性细胞死亡形式,最近因其在癌症治疗中的潜力而受到关注。研究表明,OC细胞对铁死亡高度敏感,靶向该途径可有效克服化疗耐药性并改善治疗效果。本综述系统地研究了铁死亡的分子机制及其在OC中的作用,重点关注其在肿瘤发生、进展、肿瘤微环境和耐药性中的参与情况。此外,我们强调了各种铁死亡诱导剂的研究进展,包括天然产物、小分子化合物和纳米技术,并探讨了它们在克服耐药性和改善患者预后方面的潜力。我们还讨论了基于铁死亡的OC治疗面临的挑战,如物种差异、耐药性、个性化治疗需求和临床转化问题。最终,靶向调节铁死亡为OC治疗带来了新希望。未来的研究应集中在进一步阐明其分子机制,探索有效的诱导剂和联合疗法,以提高其在精准和个性化医学中的临床适用性。